ARK Invest purchased ~281K CRISPR Therapeutics (CRSP) shares worth $14.82M after a 10% drop triggered by a $350M private offering announcement.

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the 10 most shorted biotech stocks to buy according to hedge funds. On February 17, Morgan Stanley increased its price target on CRISPR Therapeutics AG ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is among the ARK Invest Stock Portfolio: Top 10 Stock Picks for 2026, with a stake value ...

Current shareholders were thrown an unexpected curveball that they actually should have been expecting.

CRISPR Therapeutics CRSP is expected to report third-quarter 2025 earnings later this week. The Zacks Consensus Estimate for quarterly sales is pegged at $6.71 million, while that for earnings is ...

CRISPR Therapeutics AG CRSP shares moved lower Tuesday after the biotechnology company outlined plans to raise capital through a new convertible debt offering. The gene-editing firm said it intends to ...

Investors in CRISPR Therapeutics AG (Symbol: CRSP) saw new options begin trading today, for the December 5th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the Unstoppable Stocks to Buy and Hold for the Next 5 Years. On September 23, analyst Mitchell Kapoor from H.C. Wainwright reiterated a “Buy” rating on ...

This article looks at the ARK Invest Stock Portfolio: Top 10 Stock Picks for 2026. ARK Investment Management LLC, or ARK Invest, is an American investment management firm that oversees several ...